Cocrystal Pharma, Inc. filings document material-event disclosures for a clinical-stage antiviral drug developer. Recent 8-K reports furnish press releases on CDI-988, including norovirus program updates, FDA Fast Track designation, scientific conference presentations and annual financial results tied to the antiviral pipeline.
The company’s filings also record Nasdaq Capital Market status, board and executive compensation matters under the 2025 Equity Incentive Plan, stock-option grants and director changes, along with Regulation FD disclosures and exhibits related to clinical and business updates.
Cocrystal Pharma, Inc. (COCP) is a clinical-stage antiviral biopharmaceutical company developing candidates for influenza, norovirus, coronavirus and HCV. The company reported a six-month net loss of $4.36 million and used $5.09 million of cash in operations through June 30, 2025. Cash and restricted cash totaled $4.84 million, total assets were $8.51 million and stockholders' equity was $5.33 million as of June 30, 2025. The company recorded a large accumulated deficit of $337.8 million (in thousands).
The filing discloses substantial doubt about the company’s ability to continue as a going concern and states current resources are not expected to be sufficient to fund operations beyond the next 12 months without additional financing. Clinical updates show MHRA authorization and ongoing analysis for the CC-42344 Phase 2a human challenge study and Phase 1 data for CDI-988 with safety/tolerability reported up to 1,200 mg. The company continues to rely on equity offerings and its ATM program for liquidity.
Cocrystal Pharma, Inc. filed a current report to share that it has released its financial results for the fiscal quarter ended June 30, 2025. On August 14, 2025, the company issued a press release detailing its results of operations and financial condition, which is furnished as Exhibit 99.1 to this report. The company notes that this information is furnished, not filed, so it is not subject to certain liability provisions and is not automatically incorporated into other securities filings.